Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shengjun Fan

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 11, 2020
PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ PathwayShengjun Fan, Trevor Price, Wei Huang, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 15, 2018
FOXO1 inhibition potentiates endothelial angiogenic functions in diabetes via suppression of ROCK1/Drp1-mediated mitochondrial fissionYundi Shi, Shengjun Fan, Di Wang, et al.
Annals of Hematology|December 2, 2022
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myelomaYubin Kang, Pasupathi Sundaramoorthy, Cristina Gasparetto, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 11, 2020
PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ PathwayShengjun Fan, Trevor Price, Wei Huang, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 15, 2018
FOXO1 inhibition potentiates endothelial angiogenic functions in diabetes via suppression of ROCK1/Drp1-mediated mitochondrial fissionYundi Shi, Shengjun Fan, Di Wang, et al.
Annals of Hematology|December 2, 2022
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myelomaYubin Kang, Pasupathi Sundaramoorthy, Cristina Gasparetto, et al.
Pageof 3